Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralmitaront for negative symptoms in schizophrenia or schizoaffective disorder
2020-004752-16Phase 2Terminated
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Ralmitaront monotherapy with Placebo (2 arms). Primary endpoint: Change from baseline at Week 12 in BNSS avolition/apathy sub-score. Started Feb 2021; status: terminated.
02
Drugs
ralmitaront
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2020-004752-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004752-16.